On Monday, TD Cowen reaffirmed its confidence in shares of Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN) shares by maintaining a Buy rating and a price target of $1,230.00. The endorsement comes as the firm reviewed Regeneron's third-quarter earnings per share (EPS) with the company's CEO Len Schleifer.
The discussion highlighted a sustained belief in the long-term expansion of Eylea HD, Regeneron's treatment for eye diseases, despite an expected downturn in the fourth quarter. The analyst underscored that Dupixent (Dupi), Regeneron's medication for various inflammatory conditions, continues to be one of the most promising product launches in the biopharmaceutical sector.
The potential treatment of chronic obstructive pulmonary disease (COPD) with Dupixent is anticipated to further enhance the drug's market presence.
Moreover, TD Cowen emphasized the significant undervaluation of Regeneron's pipeline. The analyst pointed out that with key developments expected within the next six months, there are catalysts on the horizon that could positively influence the company's valuation. The statement by the analyst suggests a strong outlook for the company's research and development activities.
Regeneron's recent stock performance was also addressed, with the analyst describing the recent pullback in the company's share price as excessive. The firm's stance indicates a belief that the current market valuation does not fully reflect Regeneron's growth prospects and pipeline potential. This reaffirmation of the Buy rating implies a positive outlook for Regeneron's stock performance in the eyes of TD Cowen.
In other recent news, Regeneron Pharmaceuticals has seen several adjustments in its stock price targets by various analyst firms. BMO Capital Markets lowered its price target to $1,190 from $1,300, citing concerns about the company's ophthalmology product, Eylea, and upcoming competition from Amgen (NASDAQ:AMGN) and Roche.
Despite these challenges, Regeneron's management remains confident in Eylea's market position, expecting revenue growth in the second half of 2025.
Piper Sandler also reduced its price target for Regeneron to $1,195 from $1,242, due to slower-than-expected adoption of the Eylea HD treatment. Leerink Partners followed suit, cutting its target to $880 from $1,077, reflecting recalibrated earnings expectations for the coming years. Evercore ISI made a slight adjustment from $1,175 to $1,170, noting significant market pressures faced by the company.
Regeneron reported an 11% increase in total revenues for the third quarter, reaching $3.72 billion, largely driven by Dupixent's global sales. The company is currently developing around 40 clinical programs and expects interim results from a Phase II lung cancer study and pivotal data for itepekimab in COPD by 2025. These are the recent developments for Regeneron Pharmaceuticals.
InvestingPro Insights
Regeneron's recent financial data and market performance align with TD Cowen's bullish stance. According to InvestingPro data, Regeneron boasts a market capitalization of $90.76 billion, reflecting its significant presence in the biotechnology sector. The company's P/E ratio of 20.87 suggests that investors are willing to pay a premium for its earnings, potentially due to growth expectations highlighted by TD Cowen.
InvestingPro Tips indicate that Regeneron's management has been aggressively buying back shares, which often signals confidence in the company's future prospects. This aligns with TD Cowen's view on the undervaluation of Regeneron's pipeline. Moreover, the stock's recent performance supports the analyst's observation of a pullback, with InvestingPro data showing a 9.15% decline in the past week and a 16.71% drop over the last month.
Despite the recent downturn, Regeneron maintains strong financials, with InvestingPro Tips noting that cash flows can sufficiently cover interest payments and liquid assets exceed short-term obligations. This financial stability supports the company's ability to invest in its promising pipeline, as emphasized by TD Cowen.
For investors seeking a deeper understanding of Regeneron's potential, InvestingPro offers 11 additional tips, providing a comprehensive analysis to complement TD Cowen's outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.